|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical treatment of myasthenia gravis with deficiency of spleen and kidney based on combination of disease with syndrome theory显示文摘OBJECTIVE: To study the use of Jianjining in the treatment of myasthenia gravis (MG) patients with a deficiency of both spleen and kidney via the theory on the combination of disease with syndrome. METHODS: Sixty MG patients with a deficiency of both spleen and kidney were randomly divided into an treatment group (n=30) treated with Jianjining granules and Western Medicine (prednisone or pyridostigmine bromide) and a control group (n= 30) treated with Jianjining granules. The dosage of the three drugs was reduced over the course of treatment. After 3 and 6 months of treatment, the curative effect was evaluated with the muscle weakness severity scale (MWSS). RESULTS: The MWSS score after treatment declined significantly in both groups. The score in the treatment group was much lower than that in thecontrol group (P<0.05). The total effective rate was 63.33% (19/30) in the treatment group and 36.67% (11/30) in the control group after 3 months of treatment, and 80.00% (24/30) and 50.00% (15/30), respectively, after 6 months of treatment. The obvious and total effective rates in the treatment group were much higher than those in the control group (P<0.05). After 6 months of treatment, there were no obvious differences (P>0.05) in the obvious and effective rates between the 2 groups. However, the total effective rate in the treatment group was much higher than that in the control group (P<0.01). CONCLUSION: Using the theory on the combination of disease with syndrome, we found that the curative effect of Jianjining and Western Medicine on MG patients with deficiency of both spleen and kidney is worth further exploration. | Chao Jiang Ping Liu Yan Liang Shaobo Qiu Wenjing Bao Jingsheng Zhang | 2013 | Journal of Traditional Chinese Medicine2013，33，4： | 6 |
| 2 | Induction of autophagy enhances porcine reproductive and respiratory syndrome virus replication显示文摘 | Quangang Chen Liurong Fang Dang Wang Shaohua Wang Ping Li Mao Li Rui Luo Huanchun Chen Shaobo Xiao | 2011 | Virus Research2011，，2： | 1 |
| 3 | 肝细胞肝癌经肝动脉化疗栓塞后破裂:2例报告及系统回顾(英文)显示文摘Objective: Rupture of hepatocellular carcinoma (HCC) following transarterial embolization/chemoembolization (TAE/TACE) is a rare but life-threatening complication. The aim of the study was to explore the incidence, risk factors, clinical characteristics, treatment, and outcomes of this complication. Methods: We described two cases and reviewed all cases of ruptured HCC after TAE/TACE reported in the literature. Results: Our search yielded 32 cases of ruptured HCC after TAE/TACE. The overall incidences were 0.45% per patient and 0.21% per session. The mean age of the patients was 57.4 years (range 28-90 years, n=26, No. of cases with available information). Males accounted for 81% of cases (21/26). The 50% of the cases had histories of primary hypertension, diabetes or peripheral artery disease (6/12). Mean diameter of the tumors was 11.4 cm (range 3-20 cm, n=27). The 100% of cases had superficial or exophytic tumors (23/23). Portal vein thrombosis was presented in 61.5% of patients (8/13). The median interval between TAE/TACE and rupture was 2 days (range 0 hour-30 days, n=31). Management choices included emergency TAE, surgery, and conservative treatment. The overall median survival time was 7 days (n=19). Conclusion: Rupture of HCC following TAE/TACE is relatively rare but potentially life-threatening. The management is difficult and prognosis is poor. Large tumor size, superficial or exophytic tumors as well as portal vein thrombosis and comorbidities such as primary hypertension, diabetes or peripheral artery disease may be predisposing factors for rupture. | Ping Sun Zifang Song Qinggang Hu Jun Xiong Shaobo Hu Ruiqing He Qichang Zheng | 2013 | The Chinese-German Journal of Clinical Oncology2013，12，2： | 1 |
| 4 | Induction of autophagy enhances porcine reproductive and respiratory syndrome virus replication显示文摘 | Quangang Chen Liurong Fang Dang Wang Shaohua Wang Ping Li Mao Li Rui Luo Huanchun Chen Shaobo Xiao | 2011 | Virus Research2011，，2： | 1 |
| 5 | MiR-320a is Downregulated in Patients with Myasthenia Gravis and Modulates Inflammatory Cytokines Production by Targeting Mitogen-activated Protein Kinase 1显示文摘 | Zhuoan Cheng Shaobo Qiu Lin Jiang Anle Zhang Wenjing Bao Ping Liu Jianwen Liu | 2013 | Journal of Clinical Immunology2013，，3： | 1 |
| 6 | Altered let-7 expression in Myasthenia gravis and let-7c mediated regulation of IL-10 by directly targeting IL-10 in Jurkat cells显示文摘 | Lin Jiang Zhuoan Cheng Shaobo Qiu Zujun Que Wenjing Bao Chao Jiang Fangyuan Zou Ping Liu Jianwen Liu | 2012 | International Immunopharmacology2012，，2： | 1 |
| 7 | A review on the sealing structure and materials of fuel-cell stacks显示文摘Proton-exchange-membrane fuel cells(PEMFCs)have the characteristics of zero emissions,a low operating temperature and high power density,and have great potential in improving energy-utilization efficiency.However,fuel cells are still quite expensive as a result of the cost of key components,including the membranes,catalysts and bipolar plates of PEMFCs.As a result of the cost and importance of these items,most researchers have focused on improving the lifetime and performance of fuel-cell stacks in recent years.In contrast,seals,sealants and adhesives play a more mundane role in the overall performance of a fuel cell,but failure of these materials can lead to reduced system efficiency,system failure and even safety issues.Little attention has been paid to the performance and durability of these products but as other fuel-cell components improve,these seals are becoming an even more critical link in the long-term performance of fuel cells.This article highlights the importance and background of fuel-cell seals.The latest research progress on the mechanical properties and structural optimization of different sealing materials is reviewed. | Jinghui Zhao Huijin Guo Yuchen Xing Shaobo Ping Weikang Lin Yanbo Yang Zixi Wang Tiancai Ma | 2023 | Clean Energy2023，7，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员